JP7335472B2 - 生体適合性磁性材料 - Google Patents
生体適合性磁性材料 Download PDFInfo
- Publication number
- JP7335472B2 JP7335472B2 JP2019011014A JP2019011014A JP7335472B2 JP 7335472 B2 JP7335472 B2 JP 7335472B2 JP 2019011014 A JP2019011014 A JP 2019011014A JP 2019011014 A JP2019011014 A JP 2019011014A JP 7335472 B2 JP7335472 B2 JP 7335472B2
- Authority
- JP
- Japan
- Prior art keywords
- iron oxide
- magnetic material
- solution
- biocompatible
- biocompatible magnetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/001—Macromolecular compounds containing organic and inorganic sequences, e.g. organic polymers grafted onto silica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Magnetic Treatment Devices (AREA)
- Materials For Medical Uses (AREA)
Description
2つの生体適合性磁性材料を以下に記載される手順に従って作製した。
FeCl2・4H2O(900g、4.53モル)と、FeCl 3 (1327g、8.18モル)と、水(23.6L)との混合物を100L容のガラス反応器において25℃、150rpm~200rpmで撹拌した。窒素下で水酸化ナトリウム溶液(1N)を0.2kg/分~0.3kg/分の速度で反応器に添加し、pH値11~12を生じた。その後、オレイン酸(800mL、鉄1モル当たり63mL)を添加し、得られた混合物を更に60分間撹拌することにより、水溶液中に黒っぽいペーストとしてIO-OAナノ粒子を形成させた。水溶液のpHを塩酸(3N)によって1~2のpH値に調整した後、水を除去した。その後、トルエン12Lを残りの黒っぽいペーストに添加し、トルエン溶液中に粗製IO-OAナノ粒子を懸濁した。トルエン中の粗製IO-OAナノ粒子を6000rpmで15分間遠心分離して、トルエン中にIO-OAナノ粒子を得た。
生体適合性ポリマーのmPEG-シラン-750を、以下の手順に従って作製した。メトキシ-PEG(mPEG、分子量750)300g(0.4モル)と、無水コハク酸(48g、0.48モル)と、4-ジメチルアミノ-ピリジン(DMAP、19.5g、0.159モル)との混合物を、1000mL容の丸底フラスコ内にて真空(20Torr)下で2時間に亘って静置した。その混合物にトルエン600mLを添加し、次いでそれを30℃で1日間に亘って撹拌することで、mPEG-COOHを形成させた。引き続き、塩化チオニル36mL(0.48モル)を1mL/分の速度で添加し、その混合物を2時間~3時間に亘って撹拌した。その後に、トリエチルアミン333.8mL(2.4モル)を1mL/分の速度で添加することで、約6~7のpHが得られた。室温に冷やした後に、mPEG-COClを含有する混合物を、3-アミノプロピルトリエトキシシラン94.5mL(0.4モル)と室温で少なくとも8時間に亘って反応させることで、粗製mPEG-シラン-750が得られた。粗製mPEG-シラン-750は、上記反応混合物にイソプロピルエーテル9Lを添加した後に析出した。固体生成物を濾過により回収し、トルエン500mL中に再溶解させ、5000rpmで5分間に亘って遠心分離して上清を回収し、そこにイソプロピルエーテル9Lを添加した。イソプロピルエーテルから褐色の油状液体が分離し、それを真空下で乾燥させることで、生体適合性ポリマーのmPEG-シラン-750を得た。
PEG(分子量:750)300g(0.4モル)及びN-メチル-2-ピロリドン600mLを1000mL容の丸底フラスコに入れ、2時間超に亘って真空(20Torr)下で60℃まで加熱した。無水コハク酸88g(0.88モル)及び4-ジメチルアミノ-ピリジン(DMAP)19.5g(0.16モル)を添加して、30℃で2日間反応させることでジカルボキシ末端PEG(COOH-PEG)を得た。
以下の通り、トルエン中でmPEG-シラン-2000を酸化鉄ナノ粒子、すなわちIO-OAナノ粒子とコンジュゲートさせることによって生体適合性磁性材料を作製した。
250gのCOOH-mPEG-シラン-2000を10gのFeのIO-OAナノ粒子を含むトルエン溶液1L~1.2Lに添加した。得られた混合物を2時間~3時間、超音波処理した。1.5Lの脱イオン水を添加した後、その混合物を限外濾過装置によって精製し、100mLまで濃縮して、IO-OA/COOH-PEG-シラン-2000と称される生体適合性磁性材料を得た。
実施例1で作製された生体適合性磁性材料と並んで、特定の酸化鉄ナノ粒子を以下の通り特性評価するため研究を行った。
酸化鉄ナノ粒子及び生体適合性磁性材料のFe(II)/Fe(III)イオン比を、Iron Testキット(Spectroquant 1.00796.0001、Merck)によって測定した。検査キット中の試薬、すなわち、1,10-フェナントロリンはFe(III)イオンではなくFe(II)イオンに感受性であった。緩衝培質では、Fe(II)イオンは1,10-フェナントロリンと反応して、測光によって特定された赤色の複合体を形成した。試験酸化鉄ナノ粒子又は生体適合性磁性材料は、硫酸の添加によって最初に鉄イオンに分解され、得られた溶液のpHを0.8M NaHCO3を使用して2~8に調整した。Fe(II)イオンは処理の間Fe(III)イオンに変換されなかったことが観察された。アスコルビン酸を添加せずに、Fe(II)イオンのみの含有量を測定した。アスコルビン酸を添加して、全ての鉄イオンをFe(II)イオンに変換することで、全鉄イオンを更に測定した。Fe(II)イオンの含有量は、全鉄イオンに対して約4%~15%であることが特定された。詳細な結果を下記表1に示す。またこの表には、市販の薬剤であるFerahemeについて1.26%のFe(II)の含有量が含まれていることに留意する。
特定の酸化鉄ナノ粒子及び生体適合性磁性材料の構造をXRPDによって以下の通り調査した。
実施例1で作製された生体適合性磁性材料の緩和度と並んで、Ferahemeについての緩和度を以下の通り測定して研究を行った。
以下に本発明の生体適合性磁性材料を特異的標的剤とカップリングさせるプロトコルを記載する。
葉酸溶液(葉酸塩/ジメチルスルホキシド:10mg/mL)226μLを50mL容の褐色丸底フラスコに入れた。ジメチルスルホキシド(DMSO)5mL及びジシクロヘキシルカルボジイミド溶液(ジシクロヘキシルカルボジイミド/DMSO:5mg/mL)176.5μLを上記溶液に添加し、1時間撹拌した。その後、NHS溶液(N-ヒドロキシスクシンイミド/DMSO:5mg/mL)98.5μlを添加し、更に1時間撹拌した。その後、エチレンジアミン289μLを添加して、溶液Aを得た。
IO-OA/COOH-PEG-シラン-2000(4.48mg Fe/mL)を、冷脱イオン水5mLと混合して、氷浴で維持した。1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド(10-6モル)を上記溶液に添加し、30分間撹拌した。次いで、N-ヒドロキシスクシンイミド(10-6モル)をその混合物に添加し、更に30分間撹拌した。抗体My10(1mL、2μg/mL)を得られた混合物に添加し、2時間反応させた。そのようにして得られた溶液を、磁力選別装置を通過させることによって精製して、抗体とカップリングした生体適合性磁性材料、すなわちMy10コンジュゲートIO-OA/COOH-PEG-シラン-2000を得た。
本明細書で開示された特徴は全てあらゆる組合せで組み合わせることができる。本明細書で開示される各特徴は同じ、同等の、又は同様の目的を果たす代替特徴に置き換えることができる。そのため特に明記しない限り、開示される各特徴は一連の包括的な同等又は同様の特徴の例にすぎない。
Claims (10)
- 前記酸化鉄-有機酸ナノ粒子が、全鉄イオンに対して4%~8%のFe(II)イオンを含む、請求項1に記載の生体適合性磁性材料。
- 前記酸化鉄-有機酸ナノ粒子が、酸化鉄-オレイン酸ナノ粒子である、請求項1に記載の生体適合性磁性材料。
- 前記リンカーが、O、S、Si、C1~C6アルキレン、2個のカルボニル基と、2個~20個の炭素原子とを含むカルボニル部分、又は下記式:
- R1がC1~C6アルキル、C1~C10カルボニル基、又はC1~C10アミン基であり、R2がH又はC1~C6アルキルであり、R 1 が任意にメチル、カルボキシル又はアミノであり、R 2 が任意にHである、請求項5に記載の生体適合性磁性材料。
- R1が、抗体、タンパク質、ペプチド、酵素、炭水化物、糖タンパク質、ヌクレオチド、及び脂質からなる群から選択される特異的標的剤にカップリングされており、前記特異的標的剤が任意に抗体である、請求項5に記載の生体適合性磁性材料。
- 請求項1に記載の生体適合性磁性材料を作製する方法であって、
全鉄イオンに対して4%~10%のFe(II)イオンを含む酸化鉄-有機酸ナノ粒子を第1の有機溶媒中に含む第1の溶液を準備することと、
第2の有機溶媒に式(I)の生体適合性ポリマーを含む第2の溶液を準備することと、
前記第1の溶液と前記第2の溶液とを混合して混合溶液を得ることと、
前記混合溶液に水を添加し、得られた溶液を少なくとも20時間に亘って撹拌して生体適合性磁性材料を得ることと、
を含み、
前記酸化鉄-有機酸ナノ粒子が、不活性ガス雰囲気下で、水酸化物溶液をFe(II)塩を含む鉄溶液と混合することによって形成され、前記鉄溶液が1.70以上のFe(III)/Fe(II)のモル比でFe(II)塩及びFe(III)塩を含み、前記酸化鉄-有機酸ナノ粒子が、鉄1モル当たり100mL以下の量のオレイン酸を添加することで形成される、
方法。 - 前記第1の有機溶媒及び前記第2の有機溶媒が、それぞれ独立して、トルエン、脂肪族炭化水素、テトラヒドロフラン、ケトン、アルコール、アルキルエステル、又はそれらの組み合わせであり、前記不活性ガスが窒素又はアルゴンである、請求項9に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810145800.0 | 2018-02-12 | ||
CN201810145800.0A CN110157000B (zh) | 2018-02-12 | 2018-02-12 | 生物相容性磁性材料 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019137674A JP2019137674A (ja) | 2019-08-22 |
JP2019137674A5 JP2019137674A5 (ja) | 2022-01-27 |
JP7335472B2 true JP7335472B2 (ja) | 2023-08-30 |
Family
ID=65529243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019011014A Active JP7335472B2 (ja) | 2018-02-12 | 2019-01-25 | 生体適合性磁性材料 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20190247522A1 (ja) |
EP (1) | EP3524276B1 (ja) |
JP (1) | JP7335472B2 (ja) |
KR (1) | KR20190098064A (ja) |
CN (1) | CN110157000B (ja) |
AU (1) | AU2019200753B2 (ja) |
CA (1) | CA3032985A1 (ja) |
DK (1) | DK3524276T3 (ja) |
ES (1) | ES2903387T3 (ja) |
TW (1) | TWI811297B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107999037B (zh) * | 2017-12-18 | 2020-07-31 | 南京大学 | 一种磁性高分子吸附材料、制备方法和应用 |
CN115520907A (zh) * | 2022-04-14 | 2022-12-27 | 西安超磁纳米生物科技有限公司 | 一种具有活性基团的超小铁氧体纳米颗粒及其制备与应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006028032A (ja) | 2004-07-12 | 2006-02-02 | Toda Kogyo Corp | 磁性粒子含有医薬用原薬 |
JP2007277131A (ja) | 2006-04-05 | 2007-10-25 | Sanyo Chem Ind Ltd | 磁気共鳴画像用造影剤 |
JP2009531302A (ja) | 2006-02-28 | 2009-09-03 | メディカル リサーチ カウンシル | 標的化酸化鉄ナノ粒子 |
WO2009129649A1 (en) | 2008-04-22 | 2009-10-29 | Industrial Technology Research Institute | Biocompatible polymer and magnetic nanoparticle with biocompatibility |
JP2011126876A (ja) | 2009-11-20 | 2011-06-30 | Toda Kogyo Corp | 磁性酸化鉄微粒子粉末、磁性粒子含有水分散体およびその製造方法 |
JP2011519843A (ja) | 2008-05-02 | 2011-07-14 | アイティーアイ・スコットランド・リミテッド | 金属結合タンパク質、ポリペプチド、又はペプチドを含む造影剤を用いるインビボ磁気共鳴イメージング方法 |
JP2017529119A (ja) | 2014-07-14 | 2017-10-05 | メガプロ バイオメディカル カンパニー リミテッド | 免疫細胞のトラッキング方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552945B (zh) * | 2012-01-19 | 2013-09-11 | 青岛科技大学 | 一种磁性四氧化三铁纳米粒子的表面修饰方法 |
CN103405789B (zh) * | 2013-08-06 | 2015-02-11 | 哈尔滨工业大学 | 生物膜修饰的四氧化三铁纳米粒子的制备方法 |
TWI689310B (zh) * | 2014-07-11 | 2020-04-01 | 巨生生醫股份有限公司 | 治療鐵缺乏症之方法 |
US20180280545A1 (en) * | 2014-11-04 | 2018-10-04 | University Of Washington | Iron oxide nanoparticles and their synthesis by controlled oxidation |
-
2018
- 2018-02-12 CN CN201810145800.0A patent/CN110157000B/zh active Active
- 2018-11-29 US US16/204,510 patent/US20190247522A1/en not_active Abandoned
-
2019
- 2019-01-25 JP JP2019011014A patent/JP7335472B2/ja active Active
- 2019-02-01 TW TW108104248A patent/TWI811297B/zh active
- 2019-02-05 AU AU2019200753A patent/AU2019200753B2/en active Active
- 2019-02-07 CA CA3032985A patent/CA3032985A1/en active Pending
- 2019-02-11 EP EP19156555.5A patent/EP3524276B1/en active Active
- 2019-02-11 ES ES19156555T patent/ES2903387T3/es active Active
- 2019-02-11 DK DK19156555.5T patent/DK3524276T3/da active
- 2019-02-11 KR KR1020190015657A patent/KR20190098064A/ko unknown
-
2021
- 2021-11-24 US US17/535,168 patent/US20220080057A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006028032A (ja) | 2004-07-12 | 2006-02-02 | Toda Kogyo Corp | 磁性粒子含有医薬用原薬 |
JP2009531302A (ja) | 2006-02-28 | 2009-09-03 | メディカル リサーチ カウンシル | 標的化酸化鉄ナノ粒子 |
JP2007277131A (ja) | 2006-04-05 | 2007-10-25 | Sanyo Chem Ind Ltd | 磁気共鳴画像用造影剤 |
WO2009129649A1 (en) | 2008-04-22 | 2009-10-29 | Industrial Technology Research Institute | Biocompatible polymer and magnetic nanoparticle with biocompatibility |
JP2011519843A (ja) | 2008-05-02 | 2011-07-14 | アイティーアイ・スコットランド・リミテッド | 金属結合タンパク質、ポリペプチド、又はペプチドを含む造影剤を用いるインビボ磁気共鳴イメージング方法 |
JP2011126876A (ja) | 2009-11-20 | 2011-06-30 | Toda Kogyo Corp | 磁性酸化鉄微粒子粉末、磁性粒子含有水分散体およびその製造方法 |
JP2017529119A (ja) | 2014-07-14 | 2017-10-05 | メガプロ バイオメディカル カンパニー リミテッド | 免疫細胞のトラッキング方法 |
Non-Patent Citations (2)
Title |
---|
Chem. Rev.,2008年,Vol. 108,pp. 2064-2110 |
Mol Imaging Biol.,2011年,13(5),p.825-839 |
Also Published As
Publication number | Publication date |
---|---|
EP3524276B1 (en) | 2021-09-22 |
AU2019200753A1 (en) | 2019-08-29 |
JP2019137674A (ja) | 2019-08-22 |
EP3524276A1 (en) | 2019-08-14 |
DK3524276T3 (da) | 2021-12-13 |
CN110157000A (zh) | 2019-08-23 |
ES2903387T3 (es) | 2022-04-01 |
US20220080057A1 (en) | 2022-03-17 |
TWI811297B (zh) | 2023-08-11 |
KR20190098064A (ko) | 2019-08-21 |
AU2019200753B2 (en) | 2024-03-07 |
US20190247522A1 (en) | 2019-08-15 |
TW201936212A (zh) | 2019-09-16 |
CN110157000B (zh) | 2022-05-31 |
CA3032985A1 (en) | 2019-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220080057A1 (en) | Biocompatible magnetic materials | |
EP1979365B1 (en) | Functionalised nanoparticles, their production and use | |
CN111228520A (zh) | 一种细胞膜包覆的超小四氧化三铁纳米团簇及其制备和应用 | |
Zhu et al. | A novel host-guest complex based on biotin functionalized polyamine-β-cyclodextrin for tumor targeted delivery of luteolin | |
US20240000978A1 (en) | Method for immune cell tracking | |
CN112390786A (zh) | 一种具有aie特性的荧光和磁共振造影信号同时增强的两亲性分子、纳米颗粒及制备方法与应用 | |
US9309432B1 (en) | Polyethylene glycol based oligomers for coating nanoparticles, nanoparticles coated therewith, and related methods | |
Chen et al. | Branched polyethyleneimine modified with hyaluronic acid via a PEG spacer for targeted anticancer drug delivery | |
US9446153B2 (en) | Polyethylene glycol based oligomers for coating nanoparticles, nanoparticles coated therewith, and related methods | |
Gutierrez‐Ulloa et al. | Carbon nanotubes decorated with cationic carbosilane dendrons and their hybrids with nucleic acids | |
Nickels et al. | Functionalization of iron oxide nanoparticles with a versatile epoxy amine linker | |
JP6630293B2 (ja) | 鉄欠乏症の治療方法 | |
TW201114437A (en) | Magnetic nanoparticles for magnetic resonace imaging | |
KR101615734B1 (ko) | 멀티코어-셸 나노입자 | |
US20040076585A1 (en) | Nanoparticles of cyclic tetrapyrrolic compounds as gene and drug delivery carriers | |
US20230338586A1 (en) | Multifunctional contrast agents, compositions, and methods | |
KR100572673B1 (ko) | 지용성 페로플루이드, 그의 제조방법 및 용도 | |
Duanmu | Expanding applications of iron oxide nanoparticles by surface functionalization: From magnetic resonance imaging to nano-catalysis | |
Melendez | Chemical exchange saturation transfer (CEST) properties of albumin-binding and gold nanoparticle-bound Eu (III) chelates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220119 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230509 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230704 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230721 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7335472 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |